Steven Galson Appointed Acting Surgeon General
Steven Galson, MD, has been appointed acting surgeon general beginning October 1, 2007.
Steven Galson, MD, has been appointed acting surgeon general beginning October 1, 2007. Galson, a Rear Admiral with the US Public Health Service, joined the FDA in April 2001 as the Center for Drug Evaluation and Research (CDER) deputy center director and was appointed director in July 2005. Janet Woodcock, MD, will become acting director at CDER until a permanent center director is found. She will retain her position as deputy commissioner and permanent chief medical officer.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
